LONDON: genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces that the UK’s National Institute for Health and Clinical Excellence (“NICE”) has transferred the evaluation of the Genedrive® MT-RNR1 test to a new Early Value Assessment Programme (“EVA”). EVA is a new review process, created to drive innovation into the hands of healthcare…